Cargando…
Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
BACKGROUND: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876168/ https://www.ncbi.nlm.nih.gov/pubmed/20465840 http://dx.doi.org/10.1186/1471-2334-10-116 |
_version_ | 1782181676448743424 |
---|---|
author | DallaPiazza, Michelle Amorosa, Valerianna K Localio, Russell Kostman, Jay R Lo Re, Vincent |
author_facet | DallaPiazza, Michelle Amorosa, Valerianna K Localio, Russell Kostman, Jay R Lo Re, Vincent |
author_sort | DallaPiazza, Michelle |
collection | PubMed |
description | BACKGROUND: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI). METHODS: We conducted a cross-sectional study among HIV-infected patients negative for hepatitis B surface antigen and hepatitis C antibody in the Penn Center for AIDS Research Adult/Adolescent Database. Clinical and laboratory data were collected from the database at enrollment. Hypothesized determinants of significant fibrosis were modifiable risk factors associated with liver disease progression, hepatic fibrosis, or hepatotoxicity, including immune dysfunction (i.e., CD4 T lymphocyte count <200 cells/mm(3), HIV viremia), diseases associated with hepatic steatosis (e.g., obesity, diabetes mellitus), and use of antiretroviral therapy. The primary outcome was an APRI score >1.5, which suggests significant hepatic fibrosis. Multivariable logistic regression identified independent risk factors for significant fibrosis by APRI. RESULTS: Among 432 HIV-monoinfected patients enrolled in the CFAR Database between November 1999 and May 2008, significant fibrosis by APRI was identified in 36 (8.3%; 95% CI, 5.9 - 11.4%) patients. After controlling for all other hypothesized risk factors as well as active alcohol use and site, detectable HIV viremia (adjusted OR, 2.56; 95% CI, 1.02 - 8.87) and diabetes mellitus (adjusted OR, 3.15; 95% CI, 1.12 - 10.10) remained associated with significant fibrosis by APRI. CONCLUSIONS: Significant fibrosis by APRI score was found in 8% of HIV-monoinfected patients. Detectable HIV viremia and diabetes mellitus were associated with significant fibrosis. Future studies should explore mechanisms for fibrosis in HIV-monoinfected patients. |
format | Text |
id | pubmed-2876168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28761682010-05-26 Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients DallaPiazza, Michelle Amorosa, Valerianna K Localio, Russell Kostman, Jay R Lo Re, Vincent BMC Infect Dis Research Article BACKGROUND: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI). METHODS: We conducted a cross-sectional study among HIV-infected patients negative for hepatitis B surface antigen and hepatitis C antibody in the Penn Center for AIDS Research Adult/Adolescent Database. Clinical and laboratory data were collected from the database at enrollment. Hypothesized determinants of significant fibrosis were modifiable risk factors associated with liver disease progression, hepatic fibrosis, or hepatotoxicity, including immune dysfunction (i.e., CD4 T lymphocyte count <200 cells/mm(3), HIV viremia), diseases associated with hepatic steatosis (e.g., obesity, diabetes mellitus), and use of antiretroviral therapy. The primary outcome was an APRI score >1.5, which suggests significant hepatic fibrosis. Multivariable logistic regression identified independent risk factors for significant fibrosis by APRI. RESULTS: Among 432 HIV-monoinfected patients enrolled in the CFAR Database between November 1999 and May 2008, significant fibrosis by APRI was identified in 36 (8.3%; 95% CI, 5.9 - 11.4%) patients. After controlling for all other hypothesized risk factors as well as active alcohol use and site, detectable HIV viremia (adjusted OR, 2.56; 95% CI, 1.02 - 8.87) and diabetes mellitus (adjusted OR, 3.15; 95% CI, 1.12 - 10.10) remained associated with significant fibrosis by APRI. CONCLUSIONS: Significant fibrosis by APRI score was found in 8% of HIV-monoinfected patients. Detectable HIV viremia and diabetes mellitus were associated with significant fibrosis. Future studies should explore mechanisms for fibrosis in HIV-monoinfected patients. BioMed Central 2010-05-13 /pmc/articles/PMC2876168/ /pubmed/20465840 http://dx.doi.org/10.1186/1471-2334-10-116 Text en Copyright ©2010 DallaPiazza et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article DallaPiazza, Michelle Amorosa, Valerianna K Localio, Russell Kostman, Jay R Lo Re, Vincent Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients |
title | Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients |
title_full | Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients |
title_fullStr | Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients |
title_full_unstemmed | Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients |
title_short | Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients |
title_sort | prevalence and risk factors for significant liver fibrosis among hiv-monoinfected patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876168/ https://www.ncbi.nlm.nih.gov/pubmed/20465840 http://dx.doi.org/10.1186/1471-2334-10-116 |
work_keys_str_mv | AT dallapiazzamichelle prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients AT amorosavaleriannak prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients AT localiorussell prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients AT kostmanjayr prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients AT lorevincent prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients |